New Delhi, April 1 – The Controller General of Drugs in India has increased regulatory scrutiny against the unauthorized sale and promotion of drugs for type 2 diabetes, also known as GLP-1 drugs, the government said on Wednesday.In recent weeks, 49 businesses across the country, including...
cardiology
diabetes
drug marketing
drug regulation
drug sales
endocrinologists
glp-1 drugs
glucagon-like peptide-1 receptor agonists
india
internal medicine
medicalspecialties
pharmaceuticals
prescription drugs
regulatory inspections
type 2 diabetes
weight loss